Read the full press release: #BiomeaFusion #ADA2026 #icovamenib #BMF650 #GLP131 #diabetes #obesity #WeAimToCure To view or add a comment, sign in Innovative OXM-based dual GLP-1R/GIPR agonist API for advanced metabolic syndrome treatment
Exenatide's EXSCEL (2017) offered marginal MACE superiority (HR 0.91, 95% CI 0.831.00, p = 0.06), with trends toward 12% CV death reduction (HR 0.88, 95% CI 0.761.02) and 14% all-cause mortality benefit (HR 0.86, 95% CI 0.770.97), emphasizing safety alongside modest gains [48]
Two days a week of resistance training can reduce that muscle loss significantly
This $99 add-on test (available after your first month of treatment) reveals your unique GLP-1 sensitivity, allowing clinicians to anchor dose escalation to genetic predisposition rather than one-size-fits-all protocols
4 Eat smaller meals instead of very large meals
Make it a point to communicate consistently with your healthcare professional